Skip to main content
Clinical Trials/KCT0008003
KCT0008003
Completed
未知

Clinical study to comparing the pain improvement effects and Safety of injection with Conjuran®(polynucleotide) and hyruan plus® in Patients with Knee Osteoarthritis: Double-blind, Randomized, Single-center, Active-controlled

Seoul Metropolitan Government Seoul National University Boramae Medical Center0 sites60 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Diseases of the musculoskeletal system and connective tissue
Sponsor
Seoul Metropolitan Government Seoul National University Boramae Medical Center
Enrollment
60
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
May 6, 2021
Last Updated
3 years ago
Study Type
Interventional Study
Sex
All

Investigators

Sponsor
Seoul Metropolitan Government Seoul National University Boramae Medical Center

Eligibility Criteria

Inclusion Criteria

  • 1\)Adult over 40 years old
  • 2\)Patient with knee osteoarthritis of grade I\-IV according to Kellgren\-Lawrence grading scale (K\-L grade)
  • 3\)Patient who has more than one knee having a weight\-bearing pain of at least 40mm evaluated by 100mm VAS (the chosen indicator knee joint(targeted knee for this trial) can not change during this trial.)
  • 4\)Patients expected to be willing to give a written consent and comply with procedures of this clinical trial

Exclusion Criteria

  • 1\)Patient with previous traumatic history or trauma which could affect the results of this trial such as fracture of indicator knee joint(targeted knee for this trial)
  • 2\)Patient with rheumatoid arthritis or other metabolic arthritis
  • 3\)Patient with inflammation(ex: Osteomyelitis) at indicator knee joint(targeted knee joint for this trial) or around it
  • 4\)Patient who have joint replacement surgery or procedures in the indicator knee joint(targeted knee joint for this trial)
  • 5\)Patient who have hip joint osteoarthritis in ipsilateral side of the indicator knee joint(targeted knee joint for this trial)
  • 6\)Patient with other diseases that may affect the safety and efficacy evaluation of the indicator knee joint (e.g., patients with severe pain, such as complex site pain syndrome, Paget's disease, intervertebral disc prolapse, and gout, recurrent pseudo\-gout)
  • 7\)Patient who received intra\-articular hyaluronic acid injections within the previous 6 months of baseline (before study) or those who received intra\-joint steroid injections within 3 months or who received oral steroid within a month.
  • 8\)Patient who needs to take or is taking anticoagulants or platelet aggregation which affect the blood coagulation
  • Injectable anticoagulants: low molecular weight and non\-fractional heparin injections, etc.
  • Oral anticoagulants: Warfarin, Dabigatran, Rivaroxaban, etc.

Outcomes

Primary Outcomes

Not specified

Similar Trials